Bidlack JM - Search Results

1

The COVID-19 Pandemic: Reflections of Science, Person, and Challenge in Academic Research Settings.

Bidlack JM, Chang SL, Fitting S, Gendelman HE, Gorantla S, Kumar S, Marcondes MCG, Meigs DD, Melendez LM, Sariyer IK, Yelamanchili S. Bidlack JM, et al. J Neuroimmune Pharmacol. 2021 Dec;16(4):706-717. doi: 10.1007/s11481-021-10035-2. Epub 2021 Nov 26. J Neuroimmune Pharmacol. 2021. PMID: 34826061 Free PMC article.

2

Society on NeuroImmune Pharmacology COVID-19 Virtual Workshop.

Kumar S, Pendyala G, Yelamanchili SV, Seth P, Maggirwar S, Bidlack JM, Chang SL. Kumar S, et al. Among authors: bidlack jm. J Neuroimmune Pharmacol. 2021 Sep;16(3):519-530. doi: 10.1007/s11481-021-10001-y. J Neuroimmune Pharmacol. 2021. PMID: 34181181 Free PMC article.

3

The Neuroimmune Pharmacology of SARS-CoV-2.

Kumar S, Yelamanchili S, Seth P, Bidlack JM, Pendyala G, Maggirwar S, Chang SL. Kumar S, et al. Among authors: bidlack jm. J Neuroimmune Pharmacol. 2021 Dec;16(4):699-705. doi: 10.1007/s11481-021-10038-z. Epub 2021 Dec 22. J Neuroimmune Pharmacol. 2021. PMID: 34935110 Free PMC article.

4

Opioid receptors and signaling on cells from the immune system.

Bidlack JM, Khimich M, Parkhill AL, Sumagin S, Sun B, Tipton CM. Bidlack JM, et al. J Neuroimmune Pharmacol. 2006 Sep;1(3):260-9. doi: 10.1007/s11481-006-9026-2. Epub 2006 Jul 8. J Neuroimmune Pharmacol. 2006. PMID: 18040803 Review.

5

A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence.

Mathews JL, Smrcka AV, Bidlack JM. Mathews JL, et al. Among authors: bidlack jm. J Neurosci. 2008 Nov 19;28(47):12183-9. doi: 10.1523/JNEUROSCI.2326-08.2008. J Neurosci. 2008. PMID: 19020012 Free PMC article.

6

14 beta-Chlorocinnamoylamino derivatives of metopon: long-term mu-opioid receptor antagonists.

McLaughlin JP, Sebastian A, Archer S, Bidlack JM. McLaughlin JP, et al. Among authors: bidlack jm. Eur J Pharmacol. 1997 Feb 12;320(2-3):121-9. doi: 10.1016/s0014-2999(96)00904-1. Eur J Pharmacol. 1997. PMID: 9059844 Free article.

7

Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors.

McLaughlin JP, Nowak D, Sebastian A, Schultz AG, Archer S, Bidlack JM. McLaughlin JP, et al. Among authors: bidlack jm. Eur J Pharmacol. 1995 Dec 27;294(1):201-6. doi: 10.1016/0014-2999(95)00536-6. Eur J Pharmacol. 1995. PMID: 8788432 Free article.

8

The kappa-opioid receptor expressed on the mouse lymphoma cell line R1.1 contains a sulfhydryl group at the binding site.

Joseph DB, Bidlack JM. Joseph DB, et al. Among authors: bidlack jm. Eur J Pharmacol. 1994 Mar 15;267(1):1-6. doi: 10.1016/0922-4106(94)90218-6. Eur J Pharmacol. 1994. PMID: 8206123

9

kappa-Opioid binding sites on a murine lymphoma cell line.

Bidlack JM, Saripalli LD, Lawrence DM. Bidlack JM, et al. Eur J Pharmacol. 1992 Nov 2;227(3):257-65. doi: 10.1016/0922-4106(92)90003-e. Eur J Pharmacol. 1992. PMID: 1335414

10

5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting mu-opioid receptor antagonist devoid of agonist properties.

Jiang Q, Sebastian A, Archer S, Bidlack JM. Jiang Q, et al. Among authors: bidlack jm. Eur J Pharmacol. 1993 Jan 5;230(1):129-30. doi: 10.1016/0014-2999(93)90423-f. Eur J Pharmacol. 1993. PMID: 7679076 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

169 results

Search Page